Stroke Service, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
J Stroke Cerebrovasc Dis. 2013 Aug;22(6):718-24. doi: 10.1016/j.jstrokecerebrovasdis.2011.11.005. Epub 2011 Dec 17.
In elderly acute stroke patients, reperfusion therapy is often withheld. We sought to determine whether prestroke dementia contributed to poor outcomes after reperfusion therapy in these patients.
All consecutive patients ≥ 80 years of age who received intravenous (IV) or intra-arterial reperfusion therapy (IAT) were identified in our Get With the Guidelines Stroke (GWTG-S) database. Vascular risk factors, presence of dementia, and outcomes were abstracted from the medical record. Dementia was recorded when listed in the medical history or when under medical treatment. Primary outcome was in-hospital mortality. Secondary outcome was discharge destination, "favorable" (home or rehabilitation facility) versus "unfavorable" (skilled nursing facility, hospice, or death). Multivariate logistic regression models were used to assess outcomes.
Of 153 patients, 72% received IV tissue plasminogen activator (tPA), 35% IAT, and 7% both. The mean age was 85.8 ± 4.6 years; 13.6% had prestroke dementia. The in-hospital mortality rate was 35%. The likelihood of death increased with National Institutes of Health Stroke Scale (NIHSS; odds ratio [OR] 1.14; 95% confidence interval [CI] 1.07-1.21), IAT (OR 3.43; 95% CI 1.70-6.92), and dementia (OR 3.61; 95% CI 1.39-9.37), and decreased with IV tPA (OR 0.34; 95% CI 0.17-0.71). Increasing NIHSS (OR 0.90; 95% CI 0.85-0.95), symptomatic intracranial hemorrhage (OR 0.08; 95% CI 0.01-0.67), IAT (OR 0.43; 95% CI 0.22-0.84), and dementia (OR 0.37; 95% CI 0.14-0.97) decreased the likelihood of favorable discharge. In multivariate analysis, only NIHSS (OR 1.13; 95% CI 1.06-1.22) and dementia (OR 5.64; 95% CI 1.88-16.89) independently predicted death and unfavorable discharge destination.
Among the elderly, prestroke dementia is a powerful independent predictor of in-hospital mortality after acute reperfusion therapy for stroke. Future investigations of thrombolysis outcomes in the elderly are warranted.
在老年急性脑卒中患者中,常不进行再灌注治疗。我们旨在确定在这些患者中,卒中前痴呆是否会导致再灌注治疗后的不良结局。
从我们的 Get With the Guidelines-Stroke(GWTG-S)数据库中确定所有接受静脉(IV)或动脉内再灌注治疗(IAT)的年龄均≥80 岁的连续患者。从病历中提取血管危险因素、痴呆的存在和结局。当在病史中记录或正在接受治疗时,记录痴呆。主要结局是院内死亡率。次要结局是出院去向,“有利”(家庭或康复设施)与“不利”(熟练护理设施、临终关怀或死亡)。使用多变量逻辑回归模型评估结局。
在 153 例患者中,72%接受 IV 组织型纤溶酶原激活剂(tPA),35%接受 IAT,7%两者都接受。平均年龄为 85.8±4.6 岁;13.6%有卒中前痴呆。院内死亡率为 35%。随着国立卫生研究院卒中量表(NIHSS;优势比[OR]1.14;95%置信区间[CI]1.07-1.21)、IAT(OR 3.43;95% CI 1.70-6.92)和痴呆(OR 3.61;95% CI 1.39-9.37)的增加,死亡的可能性增加,而随着 IV tPA(OR 0.34;95% CI 0.17-0.71)的增加,死亡的可能性降低。NIHSS(OR 0.90;95% CI 0.85-0.95)、症状性颅内出血(OR 0.08;95% CI 0.01-0.67)、IAT(OR 0.43;95% CI 0.22-0.84)和痴呆(OR 0.37;95% CI 0.14-0.97)的增加降低了有利出院的可能性。在多变量分析中,只有 NIHSS(OR 1.13;95% CI 1.06-1.22)和痴呆(OR 5.64;95% CI 1.88-16.89)独立预测了院内死亡率和不利的出院目的地。
在老年人中,卒中前痴呆是急性再灌注治疗后卒中院内死亡率的有力独立预测因素。需要进一步研究老年人溶栓治疗的结局。